Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, shared results today of a phase I study showing…


Previous articlePsychedelic Bulletin: First Look at Field Trip’s FT-104 Molecule; MindMed Trial Halted by FDA, Changes at the Top
Next articlePT281 – Oliver Grundmann, Ph.D. – A Thorough Exploration of Kratom